broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K43389675-001-02-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.170415 | 0.701648 | 0.585173 | 0.516139 | 0.032824 | 0.059451 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000954 |
BRD-K44227013-001-06-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.765277 | -0.398639 | -0.029105 | 0.940704 | 0.0025 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000954 |
BRD-K44827188-001-06-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.096016 | -0.001077 | -0.004273 | 1 | 204,288,271,338,341,100,000,000,000,000,000 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000954 |
BRD-K46386702-001-02-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.828702 | -1.697298 | -0.008446 | 0.911564 | 0.091465 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000954 |
BRD-K49328571-001-15-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.90141 | 0.003576 | -0.008692 | 0.951202 | 21.975601 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000954 |
BRD-K49350383-001-14-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.211473 | 0.048285 | -0.02075 | 1 | 0.007107 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000954 |
BRD-K50010139-001-01-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.810441 | 8.31702 | 0.238803 | 0.95936 | 1.248564 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000954 |
BRD-K50168500-001-07-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.086497 | -5.368349 | 0.067392 | 1 | 0.298287 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000954 |
BRD-K51313569-001-07-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.739211 | 0.263487 | 0.028012 | 0.839225 | 0.010198 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000954 |
BRD-K51791723-003-01-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.363917 | 3.118934 | 0.403839 | 0.803607 | 0.499706 | 0.758438 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000954 |
BRD-K51967704-001-03-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.176841 | 0.035485 | -0.00646 | 1 | 0.000072 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000954 |
BRD-K52313696-001-12-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.228316 | 0.051959 | 0.010027 | 1 | 0.32282 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000954 |
BRD-K53414658-001-08-2 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.653582 | 3.164166 | 0.16575 | 0.865968 | 0.234052 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000954 |
BRD-K53972329-001-07-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.974198 | 0.008974 | -0.057887 | 0.990255 | 117,409,946,091,027,920,000,000 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000954 |
BRD-K54256913-001-08-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.269642 | 3.984696 | 0.468096 | 0.877728 | 1.970492 | 2.393555 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000954 |
BRD-K54955827-001-02-2 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.962796 | -2.928175 | 0.15831 | 1 | 0.000653 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000954 |
BRD-K54997624-001-06-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.740684 | 0.226666 | 0.014426 | 0.852385 | 0.020234 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000954 |
BRD-K55187425-236-05-2 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.747097 | 1.506231 | 0.033455 | 0.852434 | 0.034689 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000954 |
BRD-K56343971-001-14-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.263866 | -0.444103 | 0.049902 | 1 | 0.139314 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000954 |
BRD-K57080016-001-15-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 12.000892 | 3.228155 | -0.013826 | 1 | 4,358.899483 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000954 |
BRD-K57169635-001-04-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.0783 | 3.63149 | 0.548403 | 0.951461 | 6.285974 | 6.587804 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000954 |
BRD-K58435339-001-03-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.929849 | -0.160157 | -0.057782 | 0.941569 | 2,680.715873 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000954 |
BRD-K58529924-001-01-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.224633 | -8.28811 | 0.107815 | 1 | 1.231631 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000954 |
BRD-K58550667-001-08-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.219702 | 5.601022 | 0.685244 | 0.691657 | 0.013499 | 0.014968 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000954 |
BRD-K59317601-001-05-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.31371 | 0.543142 | 0.340327 | 0.785812 | 0.68313 | 4.206778 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000954 |
BRD-K60866521-001-07-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.097827 | -0.105386 | -0.001428 | 1 | 9.879051 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000954 |
BRD-K60997853-001-02-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.224094 | -3.68887 | 0.080119 | 1 | 0.091737 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000954 |
BRD-K61192372-001-08-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.040514 | -0.17437 | -0.012861 | 1 | 0.343087 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000954 |
BRD-K62008436-001-23-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.685837 | 0.044538 | 0.000883 | 0.832817 | 0.000268 | null | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000954 |
BRD-K62196610-001-01-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.999878 | -0.000081 | -0.006266 | 0.999939 | 0.000329 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000954 |
BRD-K62200014-003-10-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.325954 | 0.244758 | -0.006066 | 1 | 0.018735 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000954 |
BRD-K62391742-001-09-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.787618 | 6.01464 | 0.057527 | 0.86341 | 0.019472 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000954 |
BRD-K62627508-001-01-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.67001 | 1.858891 | 0.176487 | 0.811385 | 0.038984 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000954 |
BRD-K63504947-001-14-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.414007 | -0.260514 | 0.122271 | 1 | 0.024475 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000954 |
BRD-K64052750-001-22-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.242164 | -0.065503 | -0.010453 | 1 | 0.000075 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000954 |
BRD-K64881305-001-03-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.755881 | 0.119261 | -0.004659 | 0.873327 | 0.040704 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000954 |
BRD-K66175015-001-12-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | -0.306749 | 0.77704 | 0.517569 | 0.804919 | 3.882158 | 2.09743 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000954 |
BRD-K67844266-003-01-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.718775 | 0.041396 | -0.027895 | 0.864192 | 0.409602 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000954 |
BRD-K69001009-001-02-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.457634 | 0.851498 | 0.375006 | 0.845745 | 0.709617 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000954 |
BRD-K69694239-001-02-2 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.152694 | 4.87725 | 0.589303 | 0.7712 | 0.72762 | 0.784059 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000954 |
BRD-K69776681-001-03-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.1605 | 3.95062 | 0.530385 | 0.870635 | 2.242984 | 2.473898 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000954 |
BRD-K70301465-001-05-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.87664 | -0.086793 | -0.030061 | 0.912027 | 3,253.198643 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000954 |
BRD-K70401845-001-15-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.067458 | -0.023738 | -0.014915 | 1 | 52.162332 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000954 |
BRD-K73838513-003-05-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.027783 | 4.187809 | 0.393969 | 0.959203 | 6.981304 | 7.077266 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000954 |
BRD-K74514084-003-09-2 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.733286 | 1.014044 | 0.013239 | 0.913137 | 0.441107 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000954 |
BRD-K75009076-001-02-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | -1.056648 | 2.839655 | 0.198753 | 0.961195 | 11.442976 | 7.670913 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000954 |
BRD-K76210423-001-01-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.903964 | -0.130379 | -0.129553 | 0.926554 | 864.557622 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000954 |
BRD-K76239644-001-02-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.292241 | 1.478097 | 0.350383 | 0.946641 | 6.366981 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000954 |
BRD-K76674262-001-03-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.432161 | 8.261244 | 0.603514 | 0.779821 | 0.232149 | 0.295647 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000954 |
BRD-K76908866-001-07-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 5.734042 | -1.502264 | 0.113048 | 1 | 0.000162 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000954 |
BRD-K77625799-001-07-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.179946 | -1.080737 | 0.117847 | 1 | 0.073397 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000954 |
BRD-K78431006-001-15-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 2.344542 | -0.735032 | 0.045368 | 1 | 0.000192 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000954 |
BRD-K79254416-001-21-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.232768 | 0.362004 | 0.047782 | 1 | 2.845943 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000954 |
BRD-K81418486-001-44-2 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.429641 | 1.410464 | 0.236308 | 0.823156 | 0.498463 | 2.0019 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000954 |
BRD-K82135108-001-04-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.553203 | 3.892669 | 0.218235 | 0.700455 | 0.014941 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000954 |
BRD-K82746043-001-19-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.069164 | 1.28133 | 0.407542 | 0.372355 | 0.014199 | 0.015948 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000954 |
BRD-K83029223-001-01-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.664989 | 2.99549 | 0.085279 | 0.810234 | 0.002561 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000954 |
BRD-K83988098-001-02-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.885426 | 0.579097 | -0.019322 | 0.917135 | 0.000096 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000954 |
BRD-K85402309-043-01-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.241623 | -0.362429 | 0.008933 | 1 | 0.039305 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000954 |
BRD-K85606544-001-09-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.582694 | 0.348337 | 0.172854 | 1 | 0.940505 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000954 |
BRD-K86118762-001-01-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.971326 | -0.384988 | -0.063837 | 0.97985 | 1.296848 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000954 |
BRD-K86972824-001-01-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.808899 | -7.47826 | 0.10089 | 0.875458 | 0.340454 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000954 |
BRD-K87737963-001-06-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.251565 | 0.640682 | 0.116368 | 1 | 0.115939 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000954 |
BRD-K87782578-001-01-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.355083 | 2.677726 | 0.331348 | 0.947407 | 4.753932 | 7.54949 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000954 |
BRD-K87909389-003-03-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.399422 | 3.041921 | 0.486311 | 0.659395 | 0.040714 | 0.068976 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000954 |
BRD-K88510285-001-17-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.004 | 0.983639 | 0.420868 | 0.68988 | 0.128435 | 0.129488 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000954 |
BRD-K89014967-001-04-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.587113 | 1.946179 | 0.088139 | 1 | 2.011138 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000954 |
BRD-K92441787-001-04-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.719499 | -0.004897 | -0.075349 | 0.785989 | 3,618,492,379,906,624,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000954 |
BRD-K95142244-001-01-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.526583 | -0.875432 | 0.159158 | 0.942609 | 0.001195 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000954 |
BRD-K98572433-001-02-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.500196 | 1.070863 | 0.552457 | 0.937232 | 3.971169 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000954 |
BRD-K99113996-001-02-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.814992 | -0.160249 | -0.020798 | 0.92805 | 0.004054 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000954 |
BRD-A25234499-001-19-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.067039 | 0.13058 | -0.007534 | 1 | 0.020968 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000955 |
BRD-A70858459-001-01-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.622333 | -0.616202 | 0.077502 | 0.947574 | 0.000935 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000955 |
BRD-A74914197-001-02-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.091941 | 3.006775 | 0.060694 | 0.98404 | 0.714 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000955 |
BRD-K02113016-001-19-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.533962 | 0.444897 | 0.129546 | 0.770862 | 0.086484 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000955 |
BRD-K02130563-001-11-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.958514 | -3.646852 | -0.023889 | 0.980151 | 0.063358 | null | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000955 |
BRD-K03390685-001-01-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.130766 | 0.460484 | 0.108363 | 0.665645 | 0.318274 | 0.614803 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000955 |
BRD-K03406345-001-21-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.347773 | 0.490016 | 0.4191 | 0.705376 | 0.137482 | 1.556862 | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000955 |
BRD-K03449891-001-08-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.501305 | -0.186062 | -0.158302 | 0.788637 | 0.013437 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000955 |
BRD-K03765900-001-01-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.568833 | 0.133644 | -0.038626 | 0.744156 | 0.00419 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000955 |
BRD-K05804044-001-18-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.59216 | 0.267986 | 0.059097 | 0.814942 | 0.171558 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000955 |
BRD-K06814349-304-02-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.769939 | 0.94444 | -0.057752 | 0.867679 | 0.037052 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000955 |
BRD-K08109215-001-06-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.24087 | 0.89678 | 0.639054 | 0.806411 | 0.955378 | 1.98831 | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000955 |
BRD-K08542803-001-02-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | -0.275227 | 0.507056 | 0.700645 | 0.647939 | 1.164805 | 0.490496 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000955 |
BRD-K08703257-001-13-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.677648 | 1.011185 | 0.246127 | 0.860471 | 0.151437 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000955 |
BRD-K08799216-001-05-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.183075 | 5.184436 | 0.364156 | 0.882437 | 2.474737 | 2.702259 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000955 |
BRD-K09951645-001-11-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.787739 | -0.108066 | -0.024837 | 0.900333 | 0.024627 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000955 |
BRD-K11267252-001-05-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.907577 | 0.029278 | -0.027844 | 0.976036 | 307,165,063,051,846.7 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000955 |
BRD-K11630072-001-13-2 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.791571 | 2.190401 | 0.153101 | 0.932291 | 0.427603 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000955 |
BRD-K12184916-001-19-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.608242 | 1.557985 | 0.112442 | 0.735405 | 0.013795 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000955 |
BRD-K12343256-001-14-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.337245 | -0.333119 | 0.048994 | 1 | 0.00464 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000955 |
BRD-K13049116-001-04-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.860266 | -0.016097 | -0.033518 | 0.931314 | 0.009549 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000955 |
BRD-K13390322-001-06-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.744153 | 0.389942 | 0.101894 | 0.84919 | 0.023858 | null | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000955 |
BRD-K13514097-001-04-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.670664 | -0.138153 | 0.036751 | 0.862478 | 0.006429 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000955 |
BRD-K13662825-001-07-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.094265 | 4.428938 | 0.707023 | 0.642182 | 0.054133 | 0.056748 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000955 |
BRD-K14109347-001-03-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.569044 | 0.142225 | -0.022164 | 0.738122 | 0.003198 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000955 |
BRD-K15179879-001-03-2 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.074915 | 5.948679 | 0.799904 | 0.561224 | 0.100218 | 0.102991 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000955 |
BRD-K15600710-066-05-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.470548 | 3.961273 | 0.508484 | 0.785776 | 0.193523 | 0.395545 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000955 |
BRD-K16730910-001-10-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.991819 | 0.415655 | -0.03408 | 0.997497 | 1.010383 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000955 |
BRD-K17610631-001-03-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | -0.124341 | 0.457842 | 0.323281 | 0.729187 | 2.169052 | 1.335373 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000955 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.